CRMD logo

CRMD
CorMedix Inc

23,433
Mkt Cap
$660.56M
Volume
1.04M
52W High
$17.43
52W Low
$6.13
PE Ratio
4.01
CRMD Fundamentals
Price
$8.44
Prev Close
$8.42
Open
$8.41
50D MA
$7.39
Beta
1.01
Avg. Volume
989,432.17
EPS (Annual)
$2.03
P/B
1.51
Rev/Employee
$1.63M
$933.71
Loading...
Loading...
News
all
press releases
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
Zacks
News Placeholder
More News
News Placeholder
CorMedix (CRMD) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge
CorMedix reported strong Q1 results, with revenue coming at $127.4 million, far exceeding Wall Street’s guidance of around $105 million, according to Fiscal.ai data.
Stocktwits
News Placeholder
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +24.64% and +16.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -433.33% and -99.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
The Joint (JYNT) delivered earnings and revenue surprises of +166.67% and +5.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
CorMedix Inc (NASDAQ:CRMD) Receives Consensus Rating of "Moderate Buy" from Analysts
CorMedix Inc (NASDAQ:CRMD - Get Free Report) has been given a consensus rating of 'Moderate Buy' by the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One...
MarketBeat
News Placeholder
210,831 Shares in CorMedix Inc $CRMD Acquired by Del Sette Capital Management LLC
Del Sette Capital Management LLC acquired a new position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available